Last reviewed · How we verify
Fluzone®
Fluzone® is a marketed product by Vaxart, positioned in the influenza vaccine market. A key strength is the protection of its core composition through a patent expiring in 2028. The primary risk is the intense competition in the influenza vaccine market, with multiple established players.
At a glance
| Generic name | Fluzone® |
|---|---|
| Also known as | Fluzone Quadravalent, IIV4, influenza vaccine, Fluzone High Dose, trivalent inactivated influenza vaccine (TIV) |
| Sponsor | Vaxart |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- Exploratory Clinical Study of MT-2301 (PHASE2)
- Immune Defense Protein Impact On Respiratory Immune Outcomes (NA)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza (PHASE2)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone® CI brief — competitive landscape report
- Fluzone® updates RSS · CI watch RSS
- Vaxart portfolio CI